[Cytologic study of pharmaceutical pathomorphosis in breast cancer patients].
Use of a quantitation method of calculating the percentage of cells changed dystrophically (PCCD) in cytology for studying pharmaceutical pathomorphism has evidenced that the higher PCCD, i. e. the more significant the regression rate, the more considerable were cytographic changes. In the cases, which proved to be largely resistant to the administered cytostatics, PCCD was either low or there were no increased dystrophic changes on cytographs, or even the enhancement of anaplastic signs in tumor cells was noted. Thus, the use of the method under consideration to study pharmaceutical pathomorphism provides the opportunity to more, precisely determine the rate of regression, i. e. to estimate the degree of damaging of malignant cells, and also to timely recognize the development of the malignant cells resistance to cytostatics.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans
D000970:Antineoplastic Agents
Tsitologicheskoe izuchenie medikamentoznogo patomorfoza u bol'nykh rakom molochnoĭ zhelezy.